383 S. Colorow Drive
Salt Lake City
42 articles with Recursion Pharmaceuticals
Recursion today reported financial results and business updates for its second quarter ending June 30, 2021.
Lux Capital, Mubadala Capital, Obvious Ventures, and DCVC among founding group supporting underrepresented founders building next-generation healthcare companies
Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, today reported financial results for the first quarter of 2021 and provided business updates.
Recursion Pharmaceuticals, Inc. ("Recursion" or "we") announced the closing on April 20, 2021 of its initial public offering of 27,878,787 shares of its Class A common stock, which includes the exercise in full of the underwriters' option to purchase 3,636,363 additional shares of its Class A common stock, at a price to the public of $18.00 per share.
4/21/2021Investment funds continue springing up into life sciences companies across the globe. Here’s where the money’s being planted this week.
Recursion Pharmaceuticals, Inc. announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share.
After initially indicating it intended to raise $100 million in its Nasdaq debut, the Salt Lake City-based company will now look at bringing in approximately $306 million.
3/24/2021It’s March Madness in the life sciences industry, with money pouring in faster than LeBron James on a breakaway. Here’s where the big bucks went this week.
This week, four companies set sights on listing their shares on the stock market in hopes of raising significant funds to support the development of their pipelines and businesses.
Bayer Collaborates with Recursion to Strengthen Digital Drug Discovery and Advance New Therapies for Fibrotic Diseases
Digitally-powered drug discovery to address fibrotic diseases with previously undiscovered mechanisms and to deliver novel therapies to patients faster
Recursion Enters Into Global Licensing Agreement with Takeda to Develop TAK-733 in Hereditary Cancer Syndrome
Recursion , a digital biology company industrializing drug discovery, today announced it has entered into a global licensing agreement with Takeda Pharmaceutical Company Limited (Takeda) to gain rights to TAK-733, a clinical-stage MEK inhibitor, and develop it for the treatment of a hereditary cancer syndrome and related areas of oncology. “TAK-733 is a great example of the power of our approach to decode challenging
3/27/2020Pharma and life sciences companies from across the globe provide updates on their pipelines and business.
3/20/2020Companies strengthen their leadership teams and board with this week's Movers & Shakers.
Former CEO of Navire Pharma and CoA Therapeutics to lead digital biology company’s pharmaceutical business and clinical development, including its newly formed Development Corporation SALT LAKE CITY--( BUSINESS WIRE )-- Recursion , a digital biology company industrializing drug discovery, today announced the appointment of Shafique Virani, M.D., as its Chief Corporate Development Officer. In this role, Dr. Virani will serve as both Recursion’s Chief
High-tech biopharma company partnering with childcare leader, Bright Horizons, to ensure working parents have the support they need to achieve their family and career ambitions
More than 860 teams participated in the competition with the goal of developing machine learning methods that identify representations of biology from Recursion’s first-ever open-source dataset
8/23/2019Biopharma companies strengthen their senior leadership teams and boards of directors with this week's appointments.
Former VP of Talent at Intuit relocates from San Francisco to Salt Lake City to uplevel Recursion’s commitment to creating an inclusive and progressive workplace
Recursion, a next-gen biopharma company combining automated, experimental biology with artificial intelligence to discover and develop drugs at scale, today announced the closing of a $121 million Series C financing.
6/21/2019Biotech and pharma companies strengthen their leadership teams and committees with new appointments.